Record mula sa primary source
MateryalNaiskedyul ang advisory committee
AEON nag-iskedyul ng FDA Type 2a meeting para sa ABP-450 biosimilar
AEON ay nag-iskedyul ng Type 2a meeting kasama ang FDA sa Enero 21, 2026 upang magkasundo sa analytical pathway para sa ABP-450 bilang biosimilar ng BOTOX. Ang meeting ay sumunod sa positibong biosimilarity data na inilabas noong Nobyembre 2025 at inilaan upang gabayan ang susunod na hakbang patungo sa BLA submission.
Mahahalagang fact
- Na-file
- Dis 4, 2025, 02:02 PM
- Kaganapan
- Naiskedyul ang advisory committee
- Direksyon
- Neutral
- Kumpanya
AEONAEON Biopharma, Inc.- Asset
- prabotulinumtoxinA
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Kalendaryo
- Advisory committee · Ene 21, 2026 · Walang naitalang resulta
Sipi mula sa source
EX-99 2 aeon-20251204xex99.htm EX-99 Exhibit 99 Advancing a Proven Molecule Toward Full-Label Biosimilar Approval Fresh Data | New Capital | Simplified Structure – Positioned for Acceleration CORPORATE PRESENTATION / DECEMBER 2025 NYSEAMERICAN: AEON © 2 0 2 5 A E O N B I O P H A R M A This presentation includes forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements concerning possible or assumed future actions, business strategies, events or results of operations, illustrative timelines and targets for financing and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These st
Higit pa tungkol sa asset na ito
Kapansin-pansin
Ago 12, 2026
08:15 PM
AEONAEON Biopharma, Inc.AEON Biopharma: Inaasahang feedback ng FDA BPD Type 2b sa H2 2026 para sa ABP-450
Kapansin-pansin
May 14, 2026
08:10 PM
AEONAEON Biopharma, Inc.AEON nagpaplano ng FDA Type 2b meeting sa 2H26 para sa ABP-450